Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 21, 2012; 18(7): 698-703
Published online Feb 21, 2012. doi: 10.3748/wjg.v18.i7.698
Table 1 Clinical characteristics of the 52 patients n (%)
CharacteristicsPatients
Sex
Male34 (65.4)
Female18 (34.6)
Age (yr) (mean ± SD)53.8 ± 14.0
Primary site
Stomach18 (34.6)
Small intestine20 (38.5)
Abdominal cavity9 (17.3)
Colon2 (3.8)
Rectum2 (3.8)
Pelvis1 (1.9)
Prior surgical resection
Yes47 (90.4)
No5 (9.6)
Site of metastasis
Liver29 (55.8)
Abdominal cavity31 (59.6)
Pelvis6 (11.5)
Lung1 (1.9)
Bone1 (1.9)
Subcutaneous1 (1.9)
Prior response to imatinib 400 mg/d
Complete remission5 (9.6)
Partial remission27 (51.9)
Stable disease18 (34.6)
Progressive disease2 (3.8)
Receiving regional treatment prior to dose escalation
Complete tumor resection4 (7.7)
Palliative tumor resection4 (7.7)
Local Radiofrequency ablation treatment1 (1.9)
No regional treatment43 (82.7)